文献速递炎症性肠病

乌司奴单抗治疗305例克罗恩病的真实世界短期疗效:ENEIDA注册研究

Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry.
PubMed 文献 · Aliment Pharmacol Ther · 2019-06-20

多中心研究纳入305例难治性克罗恩病患者,按UNITI推荐剂量起始乌司奴单抗(约6 mg/kg IV第0周,90 mg皮下第8周)。基线HBI>4分的217例中,第8周47%、第14周58%达临床缓解;第8周和第14周FC正常化分别为46%和54%,CRP正常化分别为35%和41%。

要点

  • 基线HBI>4分患者中,第8周47%、第14周58%达临床缓解。
  • 第8周和第14周FC正常化分别为46%和54%,CRP正常化分别为35%和41%。
  • 对最近一种抗TNF制剂不耐受及既往抗TNF制剂较少与第14周临床缓解相关。

核心结论

  • 这是首个显示乌司奴单抗按推荐诱导方案治疗高度难治性克罗恩病患者真实世界有效性和安全性的研究。

研究设计与样本

  • 多中心研究,纳入2017年6月后开始乌司奴单抗治疗的克罗恩病患者305例,按推荐剂量给药(根据体重260、390或520 mg,约6 mg/kg静脉第0周,90 mg皮下第8周)。

主要发现

  • 305例患者中,既往≥2种抗TNFα治疗者64%,既往维得利珠单抗者29%。
  • 基线HBI>4分者217例(72%),其中第8周和第14周分别有101例(47%)和126例(58%)达临床缓解。
  • FC恢复正常(<250 µg/g)的患者在第8周为46%、第14周为54%。
  • CRP恢复正常(<3 mg/L)的患者在第8周为35%、第14周为41%。
  • 记录到38例不良事件,40例患者住院;对最近一种抗TNF制剂不耐受及既往抗TNF制剂较少与第14周临床缓解相关,内镜严重程度与应答不佳相关。

关键数值与推荐

  • 乌司奴单抗推荐剂量:根据体重260、390或520 mg(约6 mg/kg)静脉第0周,90 mg皮下第8周。
  • 临床缓解定义为HBI≤4分;FC正常定义为<250 µg/g;CRP正常定义为<3 mg/L。

临床怎么用

  • 在高度难治性克罗恩病患者中,按推荐诱导方案使用乌司奴单抗可观察到短期临床缓解及FC、CRP正常化。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited data of ustekinumab administered according to the doses recommended in the UNITI studies. AIM: To assess the real-world, short-term effectiveness of ustekinumab in refractory Crohn's disease (CD) METHODS: Multicentre study of CD patients starting ustekinumab after June 2017 at the recommend dose (260, 390 or 520 mg based on weight ~6 mg/kg IV week 0 and 90 mg subcutaneously week 8). Values for Harvey-Bradshaw Index (HBI), C-reactive protein (CRP) and faecal calprotectin (FC) were recorded at baseline and at weeks 8 and 14. Demographic and clinical data, previous treatments, AEs and hospitalisations were documented. Possible predictors of clinical remission were examined. RESULTS: Three hundred and five patients were analysed (≥2 previous anti-TNFα therapies 64% and vedolizumab 29%). At baseline, 217 (72%) had an HBI >4 points. Of these, 101 (47%) and 126 (58%) achieved clinical remission at weeks 8 and 14, respectively. FC levels returned to normal (<250 µg/g) in 46% and 54% of the patients at weeks 8 and 14 respectively. CRP returned to normal (<3 mg/L) in the 35% and 41% of the patients at week 8 and 14 respectively. AEs were recorded in 38, and 40 patients were hospitalised. Intolerance to the most recent anti-TNF agent and fewer previous anti-TNF agents were associated with clinical remission at week 14. Endoscopic severity was associated with poor response. CONCLUSION: This is the first study to show the real-world effectiveness and safety of ustekinumab administered according to the recommended induction regimen in a cohort of highly refractory CD patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Iborra M, Beltrán B, Fernández-Clotet A, et al. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2019. PMID: 31222872. doi:10.1111/apt.15371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。